

WEST Search History

DATE: Wednesday, January 17, 2007

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L9	l7 and himbacine	7
<input type="checkbox"/>	L7	L6 and thrombin	68
<input type="checkbox"/>	L6	514/337	1238
<input type="checkbox"/>	L5	l1 and thrombin	44
<input type="checkbox"/>	L1	546/268.1	467

END OF SEARCH HISTORY

=> s l3

L4 3 L3

=> d abs bib hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AB A method of treating a condition comprises administering to a mammal in need of such treatment an effective amount of at least one bi- or tricyclic compound (Markush included), or a pharmaceutically acceptable isomer, salt, solvate or co-crystal form thereof. The condition is a cardiovascular or circulatory disease or condition, an inflammatory disease or condition, a respiratory tract or disease or condition, cancer, acute renal failure, astrogliosis, a fibrotic disorder of the liver, kidney, lung or intestinal tract, Alzheimer's disease, diabetes, diabetic neuropathy, rheumatoid arthritis, neurodegenerative disease, neurotoxic disease, systemic lupus erythematosus, multiple sclerosis, osteoporosis, glaucoma, macular degeneration, psoriasis, radiation fibrosis, endothelial dysfunction, a wound or a spinal cord injury, or a symptom or result thereof. Combination therapy with other therapeutically effective agents is also disclosed.

AN 2004:802569 CAPLUS

DN 141:289089

TI Methods of therapeutic use of thrombin receptor antagonists

IN Chackalamannil, Samuel; Xia, Yan; Veltri, Enrico P.; Chelliah, Mariappan V.; Wu, Wenxue; Graziano, Michael P.; Kosoglou, Teddy; Chintala, Madhu

PA Schering Corp, USA

SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 412,982. CODEN: USXXCO

DT Patent


LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004192753	A1	20040930	US 2003-705282	20031110
	US 2002026050	A1	20020228	US 2001-880222	20010613
	US 6645987	B2	20031111		
	US 2003216437	A1	20031120	US 2003-412982	20030414
	US 2004176418	A1	20040909	US 2004-755066	20040109
	AU 2004289310	A1	20050526	AU 2004-289310	20041109
	CA 2545060	A1	20050526	CA 2004-2545060	20041109
	WO 2005046688	A2	20050526	WO 2004-US37519	20041109
	WO 2005046688	A3	20050929		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1682140	A2	20060726	EP 2004-810675	20041109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
	CN 1878552	A	20061213	CN 2004-80033135	20041109

NO	2006002675	A	20060808	NO	2006-2675	20060609
PRAI	US 2000-211724P	P	20000615			
	US 2001-880222	A2	20010613			
	US 2002-373072P	P	20020416			
	US 2003-412982	A2	20030414			
	US 2003-671216	A2	20030925			
	US 2003-705282	A2	20031110			
	WO 2004-US37519	W	20041109			
OS	MARPAT 141:289089					
IT	380893-99-2					
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)					
	(therapeutic use of thrombin receptor antagonists)					
RN	380893-99-2 CAPLUS					
CN	Benzonitrile, 2-[6-[(1E)-2-[(3R,3aR,4S,5R,6S,7aS)-5-ethyloctahydro-7a-hydroxy-3,6-dimethyl-1-oxo-4-isobenzofuranyl]ethenyl]-3-pyridinyl]- (9CI)					
	(CA INDEX NAME)					

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Eleven title compds. are claimed. Thus, phosphonate (I) in THF at 0° was treated with BuLi and then with Ti(OiPr)₄ followed by stirring at room temperature and addition of aldehyde (II) followed by stirring for 1.5 h to give 62% title compound (III). Title compds. inhibited thrombin receptor with IC₅₀ = 1-1000 nM.

AN 2004:633287 CAPLUS
 DN 141:174354
 TI Preparation of nor-seco himbacine derivatives as thrombin receptor antagonists
 IN Chackalamannil, Samuel; Chelliah, Mariappan V.; Xia, Yan
 PA Schering Corp, USA
 SO U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Pat. Appl. 2004 6,105.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004152736	A1	20040805	US 2003-671216	20030925
	US 2002026050	A1	20020228	US 2001-880222	20010613
	US 6645987	B2	20031111		
	US 2004006105	A1	20040108	US 2003-457256	20030609
	US 6894065	B2	20050517		
	US 2004176418	A1	20040909	US 2004-755066	20040109
	AU 2004276327	A1	20050407	AU 2004-276327	20040923
	CA 2540163	A1	20050407	CA 2004-2540163	20040923
	WO 2005030712	A2	20050407	WO 2004-US31495	20040923
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663965	A2	20060607	EP 2004-789042	20040923
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014592	A	20061107	BR 2004-14592	20040923
	NO 2006001797	A	20060519	NO 2006-1797	20060424
PRAI	US 2000-211724P	P	20000615		
	US 2001-880222	A3	20010613		
	US 2003-457256	A2	20030609		
	US 2002-373072P	P	20020416		
	US 2003-412982	A2	20030414		
	US 2003-671216	A2	20030925		
	US 2003-705282	A2	20031110		
	WO 2004-US31495	W	20040923		
OS	MARPAT 141:174354				
IT	735287-86-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(claimed compound; preparation of nor-seco himbacine derivs. as thrombin receptor antagonists)				
RN	735287-86-2 CAPLUS				
CN	Benzonitrile, 2-[6-[(1E)-2-[(3R,3aR,4S,5R,6S,7aS)-octahydro-7a-hydroxy-3,5,6-trimethyl-1-oxo-4-isobenzofuranyl]ethenyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.
Double bond geometry as shown.



IT 380893-99-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of nor-seco himbacine derivs. as thrombin receptor antagonists)
 RN 380893-99-2 CAPLUS
 CN Benzonitrile, 2-[6-[(1E)-2-[(3R,3aR,4S,5R,6S,7aS)-5-ethyloctahydro-7a-
 hydroxy-3,6-dimethyl-1-oxo-4-isobenzofuranyl]ethenyl]-3-pyridinyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = alkyl, n = 0 - 2; R1-2 = H, alk(en)yl, (di/tri)fluoroalkyl, cycloalkyl, (hetero)aryl, etc.; R3 = H, OH, alkoxy, amino, sulfinyl, sulfonyl, carboxy, etc.; Het = mono-, bi- or tricyclic heteroarom. group of 5 - 14 atoms; R8,10-11 = R1, OR1 provided that when the optional double bond is present, R10 is absent; R9 = H, OH, alkoxy, halo(alkyl); B = alkyl(oxy/thio/amino), carboxamide, etc.; X = O, N- when the double dotted line is a single bond or X = H, OH, NH- when the bond is absent; Y = O, S, (H,H), (H,OH), etc.; R15 is absent when the double dotted line represents a single bond; R15 is H, alkyl, amino or alkoxy when the bond is absent; R22-23 = H, alk(en/yn)yl, heterocycloalkyl, aryl, etc.] were prepared Over 100 synthetic examples were disclosed. E.g., II was prepared in 4 steps and reduced to the triene (THF, Lindlar's catalyst, quinoline, 1 atm H₂) and subsequently heated to give a homochiral Diels-Alder adduct (m-xylene, 185°C, 10 h). Debenzylation, olefin reduction (i. EtOAc, 10% Pd/C, H₂, 5 h; ii. MeOH, PtO₂, 50 psi H₂, 2 days) afforded the corresponding carboxylic acid (35% yield from II) and was converted to aldehyde III (CH₂Cl₂, ClCOCOC1, DMF; Pd(PPh₃)₄, (n-Bu)₃SnH, 0°C, 3 h) in 48% yield. III was coupled to substituted arylmethyl diethylphosphonates (THF, n-BuLi, Ti(OPr-i)₄, 0°C - room temperature) to afford example compds.; e.g. IV. Certain example compds. of the invention had IC₅₀ = 1 - 1000 nM for the thrombin receptor. I are useful for the treatment of atherosclerosis, restenosis, hypertension, arrhythmia, etc.

AN 2001:923791 CAPLUS

DN 136:37526

TI Synthesis of γ -lactone-alkyl-pyridines as thrombin receptor antagonists

IN Chackalamannil, Samuel; Chelliah, Mariappan; Xia, Yan

PA Schering Corporation, USA
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001096330	A2	20011220	WO 2001-US19025	20010613
	WO 2001096330	A3	20020613		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2410177	A1	20011220	CA 2001-2410177	20010613
	AU 200166900	A	20011224	AU 2001-66900	20010613
	EP 1294714	A2	20030326	EP 2001-944492	20010613
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001011991	A	20030401	BR 2001-11991	20010613
	HU 200303081	A2	20031229	HU 2003-3081	20010613
	JP 2004503551	T	20040205	JP 2002-510472	20010613
	NZ 523075	A	20040528	NZ 2001-523075	20010613
	IN 2002CN02036	A	20050225	IN 2002-CN2036	20021211
	NO 2002005965	A	20030214	NO 2002-5965	20021212
	ZA 2002010099	A	20040312	ZA 2002-10099	20021212
PRAI	US 2000-211724P	P	20000615		
	WO 2001-US19025	W	20010613		
OS	MARPAT 136:37526				
IT	380893-99-2P				
	RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(drug; synthesis of γ -lactone-alkyl-pyridines as thrombin receptor antagonists)			
RN	380893-99-2	CAPLUS			
CN	Benzonitrile, 2-[6-[(1E)-2-[(3R,3aR,4S,5R,6S,7aS)-5-ethyloctahydro-7a-hydroxy-3,6-dimethyl-1-oxo-4-isobenzofuranyl]ethenyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.
 Double bond geometry as shown.

